The biology behind the world’s most talked-about hormone
Natural GLP-1 survives for about a minute in the human body. Semaglutide, the medicine built from it, lasts a week. That six-order-of-magnitude gap is the real story behind Ozempic, Wegovy and Mounjaro — and it starts with a hormone most people had never heard of twenty years ago.
By Ibumix · 6-minute read
Every week, millions of people open a refrigerator, remove a pen about the size of a marker, and inject a few drops of clear liquid under the skin. The process takes less than a minute. Within days, appetite fades, meals shrink without effort, and blood sugar settles — not because anyone found sudden willpower, but because one hormone in the gut has been copied, modified and made to last roughly ten thousand times longer than nature ever intended.
That hormone is GLP-1. Understanding why it vanishes so fast, and what it took to stop it vanishing, explains more about modern pharmaceutical science than the drug itself ever could. Discovering an effective molecule, it turns out, is only half the battle. Getting it to survive long enough to work is the other half — and GLP-1 is one of the clearest examples in medicine of what that second battle actually costs.
A revolution that began in the gut
For most of the twentieth century, obesity was treated as a question of self-control. The advice was simple: eat less, exercise more. It wasn’t wrong, exactly — but it was incomplete. Two people on similar diets, living similar lives, could end up with entirely different outcomes. Some stayed lean without trying. Others fought constant hunger and regained every pound they lost.
The difference, it turned out, was rarely character. It was biology. The body runs a continuous negotiation between the stomach, intestines, pancreas, liver and fat tissue, all reporting back to the brain on how much energy is stored and how much more is needed. That negotiation happens through hormones, and it was shaped over millions of years in a world where food shortages were the normal state of affairs. The same wiring that once kept our ancestors alive through famine now operates in a world of constant abundance — which is a large part of why modern obesity is not simply a failure of willpower operating against unlimited food, but ancient signalling systems doing exactly what they evolved to do, in an environment they were never built for.
One hormone in that negotiation has become more studied than almost any other molecule in modern medicine. Twenty years ago, almost nobody outside a research lab had heard of it. Its name is GLP-1.
The body’s own meal notification system
Within minutes of the first mouthful of a meal, cells lining the small intestine detect the arriving nutrients and start releasing chemical messengers into the bloodstream. One of the most important is Glucagon-Like Peptide-1 — GLP-1 — and it doesn’t send one message. It broadcasts several at once:
To the brain: hunger can begin to switch off.
To the stomach: slow down, release food more gradually.
To the pancreas: prepare insulin, glucose is arriving.
To the liver: reduce unnecessary glucose production.
The result is a finely balanced response: fuller sooner, full for longer, blood sugar rising gradually, insulin released only when it’s needed. It is exactly the kind of coordinated signalling that makes GLP-1 such an attractive drug target — a medicine built on this pathway isn’t forcing the body into an artificial state, it’s amplifying a pathway the body already runs on its own [3]. But nature built in a safeguard on how long that amplification could last.
Nature designed it to disappear
Here is the fact that surprises most people: natural GLP-1 is broken down by an enzyme called dipeptidyl peptidase-4, or DPP-4, within roughly one to two minutes of release [1]. At first that looks like poor design. Why manufacture a hormone this useful only to destroy it almost immediately?
The answer is control. A hormone that stayed active for hours after every meal would keep suppressing appetite long after the signal was needed. Removing it within minutes is what lets the body respond precisely to what is happening right now, rather than to what happened at breakfast. Evolutionarily, that is elegant. Pharmaceutically, it is a serious problem: a medicine that vanishes in sixty seconds would need to be given continuously to do any good at all.
So the question researchers faced was this: could a natural hormone be redesigned to keep every one of its beneficial effects, while surviving not for minutes, but for an entire week? The answer — semaglutide, engineered to resist DPP-4 and bind to albumin so it circulates for roughly seven days instead of two minutes [2] — became one of the more consequential achievements in modern medicinal chemistry, and the subject of the next article in this series.
Update, 6 July 2026: That same molecule just crossed another threshold in the UK. Novo Nordisk’s oral semaglutide tablet — approved by the MHRA on 11 June 2026 specifically for weight loss, at doses up to 25mg — went on commercial sale on 3 July. The half-life engineering described above hasn’t changed; what’s new is that patients can now take this week-long-acting hormone as a tablet rather than an injection. Making a peptide last longer in the blood and getting it to survive the swallow are two separate engineering problems — and the second is the subject of the next article in this series.
Peptide or hormone? Why the distinction matters
One confusion is worth clearing up before going further. People use “peptide drug”, “hormone”, “protein medicine” and “biologic” almost interchangeably, but they describe different things. A peptide describes what a molecule is — a short chain of amino acids. A hormone describes what it does — carries an instruction from one part of the body to another. GLP-1 is both: a peptide hormone, in the same family as insulin, glucagon and GIP (the hormone tirzepatide also targets).
The distinction matters because peptides behave nothing like conventional medicines. A small molecule such as ibuprofen is compact, chemically stable and readily absorbed through the gut wall. A peptide is large, flexible and delicate — and to the digestive system, it looks almost exactly like dietary protein. The system built to break down a piece of grilled chicken cannot tell the difference between that chicken and a carefully engineered peptide medicine. Both are just chains of amino acids waiting to be taken apart.
That single biological fact — that the gut cannot distinguish a medicine from a meal — is why turning a GLP-1 injection into an ordinary tablet has become one of the harder engineering problems in modern pharmaceutical science, and why the medicines that manage it need considerably more than a clever molecule. They need a way to survive the journey.
The other half of the battle
Discovering an effective molecule is only half the battle. Getting it into the body intact, in a form that survives long enough to work, is the other half — and it is where a great deal of the actual engineering in pharmaceutical science happens, largely out of sight. GLP-1’s two-minute lifespan is a dramatic version of a problem that shows up, in smaller ways, across almost every drug class: an active ingredient is only as good as its ability to arrive where it’s needed, intact and in usable form.
It’s the same question Ibumix works on, several steps along from GLP-1. Ibumix’s own platform is built around lipid chemistry — glyceryl caprate (GCC) — that self-assembles into a liquid-crystalline structure capable of carrying a drug in suspension rather than leaving its survival to the manufacturing process. Today that chemistry delivers established small molecules, including ibuprofen and naproxen, in liquid form. The underlying question is the one this article keeps returning to: not just whether a molecule works, but whether it survives long enough, in a form stable enough, to still be working when it arrives.
The next article in this series picks up exactly where this one ends: the three separate battles — stomach acid, the gut wall, and the bloodstream itself — that any oral peptide has to win before it can become a tablet at all.
Sources
- [1] Holst JJ. The Physiology of Glucagon-like Peptide 1. Physiological Reviews (2007). journals.physiology.org
- [2] Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Nature Reviews Drug Discovery. nature.com
- [3] Drucker DJ. The biology of incretin hormones. Cell Metabolism (2006). cell.com
Ibumix is developing a series of new liquid drug delivery platforms built on glyceryl caprate (GCC) lipid chemistry, with a patent estate covering the underlying formulation and device.